poisar

Stocks · News reference

BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID

Fiscal.ai

BioVie Inc. announced new biomarker findings from its Phase 2 ADDRESS-LC trial of bezisterim, which were presented at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    BioVie Reports 3Q 2026 Financial Results

    BioVie Inc. reported its third-quarter 2026 financial results, noting a wider quarterly loss driven by increased research and development expenses for its Long COVID program.